Bifunctional PROTAC Compounds for IRAK-4 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with overexpression or aggregation of Interleukin-1 receptor-associated kinase 4 (IRAK-4) are hindered by non-specific effects and the inability to effectively target and modulate IRAK-4, limiting the development of effective therapeutic agents.
Innovation Solution
Development of bifunctional compounds, known as proteolysis targeting chimeric (PROTAC) compounds, which comprise an E3 ubiquitin ligase binding moiety and a target protein binding moiety, allowing for the recruitment of IRAK-4 to an E3 ubiquitin ligase for degradation and inhibition, leveraging the substrate specificity of E3 ligases like VHL, cereblon, MDM2, and IAPs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bifunctional PROTAC compounds are used to target IRAK-4, then specificity of inhibition is improved, but device complexity increases due to the dual-moiety structure
Solution Approach 1:
The PROTAC compound is segmented into two distinct functional moieties: an E3 ligase binding moiety and an IRAK-4 binding moiety, connected by a linker. This segmentation allows each moiety to independently perform its function - the E3 ligase moiety recruits the ubiquitination machinery while the IRAK-4 moiety ensures target-specific binding, thereby achieving high specificity without requiring the entire molecule to be complex in a single functional unit
Solution Approach 2:
The linker serves as an intermediary element connecting the E3 ligase binding moiety and the IRAK-4 binding moiety. This intermediary structure enables the two functional moieties to be spatially separated yet functionally connected, allowing the compound to bridge the gap between the E3 ligase and IRAK-4 proteins and facilitate their interaction through ubiquitination
2Ease of operation
If small molecules are used to target protein-protein interactions, then ease of administration is improved, but binding affinity deteriorates due to shallow interaction interfaces
Solution Approach 1:
The PROTAC compound design allows the bound proteins (E3 ligase and IRAK-4) to perform the degradation function themselves without requiring additional external machinery. Once the PROTAC brings the E3 ligase into proximity with IRAK-4, the cellular ubiquitination and proteasomal degradation systems automatically process the target protein, eliminating the need for complex external degradation mechanisms
Solution Approach 2:
The invention changes the functional parameter of the small molecule from direct inhibition to indirect degradation facilitation. By transforming the mechanism of action from blocking protein-protein interaction to enabling targeted ubiquitination, the compound achieves potent and specific degradation of IRAK-4 while maintaining the administrative advantages of small molecule therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bifunctional compounds enable targeted ubiquitination and degradation of IRAK-4, potentially treating conditions such as cancer, inflammatory diseases, and cardiovascular diseases by modulating protein levels, thereby addressing the limitations of existing treatments.
Implementation Method 1
bifunctional compounds, known as proteolysis targeting chimeric (PROTAC) compounds, which comprise an E3 ubiquitin ligase binding moiety and a target protein binding moiety, allowing for the recruitment of IRAK-4 to an E3 ubiquitin ligase
Implementation Method 2
These bifunctional compounds enable targeted ubiquitination and degradation of IRAK-4
Implementation Method 3
targeted ubiquitination and degradation of IRAK-4
Data Source
AI summary
The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.